New drug combo aims to stall prostate cancer in chinese men
NCT ID NCT05171387
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This study tests whether adding darolutamide to standard hormone therapy (ADT) helps Chinese men with a high-risk form of prostate cancer that has not spread but is no longer responding to hormone therapy alone. Darolutamide blocks the effects of male hormones on cancer cells, potentially slowing tumor growth. Researchers will measure how well the treatment lowers PSA levels, a marker of cancer activity, and monitor for side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
darolutamide
What this could lead to
If successful, this could confirm darolutamide as an effective treatment option for Chinese men with this type of prostate cancer, potentially slowing disease progression.
What could go wrong
This is a Phase 2 study with a small number of participants, so results may not be conclusive. Side effects from darolutamide or hormone therapy are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Many Locations
Multiple Locations, China